Pilot Single Arm, Single Center, Open Label Trial of Pembrolizumab in Patients With Intermediate and High Risk Smoldering Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase 0
Latest Information Update: 03 Apr 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 26 Mar 2018 Planned End Date changed from 1 Jul 2019 to 1 Jul 2021.
- 26 Mar 2018 Planned primary completion date changed from 1 Jul 2019 to 1 Jul 2020.
- 12 Dec 2017 Results (n=12) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology